Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients on thrice-weekly standard hemodialysis for > 3 months
Patients willing to provide written informed consent.
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients on thrice-weekly standard hemodialysis for > 3 months
Patients willing to provide written informed consent.

Exclusion Criteria

Patients who are likely to receive kidney transplant within the following 1 year
Patients considered by investigator to have difficulty in participation
Patients whose life expectancy < 12 months
...
Patients who are likely to receive kidney transplant within the following 1 year
Patients considered by investigator to have difficulty in participation
Patients whose life expectancy < 12 months
Patients with recent major cardiovascular disease during the last 6 months
Patients with any uncontrolled malignant disease
Patients with active infectious or uncontrolled inflammatory disorders

Summary

Conditions
End Stage Renal Disease
Type
Interventional
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 20 years and 75 years
Gender
Both males and females

Inclusion Criteria

Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients on thrice-weekly standard hemodialysis for > 3 months
Patients willing to provide written informed consent.
Patients with a vascular access capable of delivering consistently a high blood flow rates ( ≥ 300 mL/min)
Patients on thrice-weekly standard hemodialysis for > 3 months
Patients willing to provide written informed consent.

Exclusion Criteria

Patients who are likely to receive kidney transplant within the following 1 year
Patients considered by investigator to have difficulty in participation
Patients whose life expectancy < 12 months
...
Patients who are likely to receive kidney transplant within the following 1 year
Patients considered by investigator to have difficulty in participation
Patients whose life expectancy < 12 months
Patients with recent major cardiovascular disease during the last 6 months
Patients with any uncontrolled malignant disease
Patients with active infectious or uncontrolled inflammatory disorders

Locations

Seoul
Seoul
Seoul
Anyang, Gyeonggi-do
Seoul
...
Seoul
Seoul
Seoul
Anyang, Gyeonggi-do
Seoul
Seoul

Tracking Information

NCT #
NCT02092194
Collaborators
Boryung Pharmaceutical Co., Ltd
Investigators
Study Director: Won-Yong Cho, MD Korea University